Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment

INTRODUCTION: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. METHODS: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Satoshi, Shinmyozu, Kaori, Kawakami, Daisuke, Yamauchi, Miho, Ikeda, Shuhei, Hattori, Yorito, Yamamoto, Rintaro, Hayakawa, Naoki, Ihara, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158162/
https://www.ncbi.nlm.nih.gov/pubmed/34095441
http://dx.doi.org/10.1002/trc2.12182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158162/
https://www.ncbi.nlm.nih.gov/pubmed/34095441
http://dx.doi.org/10.1002/trc2.12182

Ejemplares similares